Alaunos Therapeutics (NASDAQ:TCRT) released proof-of-concept data from two separate diet-induced obesity (DIO) mouse studies on Monday, marking a strategic pivot toward non-hormonal metabolic treatments.
Ocugen (NASDAQ:OCGN) announced Monday that it has completed patient enrollment for its pivotal Phase 3 liMeliGhT clinical trial, evaluating OCU400 for the treatment of retinitis pigmentosa (RP).
Pharvaris (NASDAQ:PHVS) dominated the clinical spotlight at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 meeting on Monday, unveiling full data from its RAPIDe-3 and CHAPTER-1 trials.
Apogee Therapeutics (NASDAQ:APGE) solidified its clinical roadmap for 2026 on Monday, reporting a year-end cash position of $902.9 million.
Xeris Biopharma Holdings (NASDAQ:XERS), a Chicago-based specialty pharmaceutical company focused on therapies for rare endocrine and metabolic diseases, on Monday reported net income of $11.1 million for its fourth quarter ended December 31, 2025.
uniQure (NASDAQ:QURE) entered 2026 with a dual narrative of clinical progress and regulatory complexity.
Compugen (NASDAQ:CGEN) delivered a transformative fiscal 2025, reporting a sharp pivot to profitability and a significantly bolstered balance sheet.
Zymeworks (NASDAQ:ZYME) reported a significant narrowing of its annual losses and a double-digit jump in revenue on Monday, driven by the continued maturation of its oncology-focused licensing portfolio.
RadNet (NASDAQ:RDNT) reported record fourth-quarter and full-year 2025 results today, underscoring the success of its dual-track strategy to dominate both physical outpatient imaging and the burgeoning clinical AI market.
Belite Bio (NASDAQ:BLTE), a clinical-stage biopharmaceutical company focused on developing therapies for degenerative retinal diseases, today announced positive topline results from its pivotal Phase 3 DRAGON trial evaluating tinlarebant, an oral retinol binding protein 4 (RBP4) antagonist, for the treatment of adolescent Stargardt disease.
Merck (NYSE:MRK) unveiled groundbreaking final results from the Phase 3 KEYNOTE-B96 trial today at the ESGO 2026 Congress, demonstrating that a Keytruda-based regimen can extend the lives of patients facing one of the most aggressive forms of ovarian cancer.
ALX Oncology Holdings (NASDAQ:ALXO) reported fourth-quarter and full-year 2025 results on Friday, highlighting a fundamental shift toward a biomarker-driven strategy that could redefine patient selection for its immuno-oncology pipeline.
